Form 4: Rapport Therapeutics Director James Healy Granted Stock Options

Rapport Therapeutics, Inc. Director James Healy has been granted 21,850 stock options with an exercise price of $10.95, vesting based on continued service.

Summary

• James Healy, a Director and 10% Owner of Rapport Therapeutics, Inc. (RAPP), was granted 21,850 stock options.
• The transaction occurred on June 17, 2025.
• The exercise price for these options is $10.95 per share.
• The options will vest upon the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders, contingent on Mr. Healy's continued service.
• The options have an expiration date of June 17, 2035.
• Following this transaction, Mr. Healy beneficially owns 21,850 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine event that aligns management interests with shareholders, generally viewed as a neutral to slightly positive development for corporate governance and long-term incentives.

Positives

• The grant of stock options to Director James Healy aligns his interests with those of the shareholders, as the value of the options is tied to the company's stock performance.
• The options were granted at an exercise price of $10.95, which is a common method of incentivizing long-term commitment and performance.

Negatives

• No immediate negatives are apparent from this routine insider transaction filing.

Risks

• No specific risks are mentioned in this Form 4 filing, which primarily reports insider transactions.

Future Outlook

The stock options granted to Director James Healy are subject to a vesting schedule, which will occur upon the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders, provided his continued service to the company. The options have a long-term expiration date of June 17, 2035.

Industry Context

The granting of stock options to directors is a standard practice across various industries, particularly in the biotechnology and pharmaceutical sectors where long-term incentives are crucial for retaining talent and aligning leadership interests with company growth and shareholder value. This practice is consistent with typical corporate governance structures aimed at incentivizing performance.

Comparison to Industry Standards

• The grant of 21,850 stock options to a director with an exercise price of $10.95 and a 10-year term is a common form of equity compensation.
• While specific comparable companies or projects are not detailed in this filing, such grants are generally in line with compensation practices for directors in similar-sized biotech companies, where equity incentives are a significant component of overall compensation packages to encourage long-term commitment and performance.

Related Party Transactions

• This document reports a related party transaction, specifically the grant of stock options from Rapport Therapeutics, Inc. to its Director, James Healy, as a form of compensation.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can positively impact shareholders by aligning the director's financial interests with the company's long-term performance and stock appreciation.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest upon the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders, subject to continued service.
• Following vesting, the options can be exercised by the reporting person at the specified exercise price until their expiration date of June 17, 2035.

Key Dates

Keywords

Rapport Therapeutics, RAPP, SEC Form 4, Insider transaction, Stock option grant, Director compensation, Equity compensation, Beneficial ownership